Breast Cancer Prognosis Assessment

Name: Breast Cancer Prognosis Assessment
Brand: CapitalBio Technology Co., Ltd.

This test uses RT-qPCR technology to detect the expression of 16 tumor-related genes (proliferation, invasion, HER2, and hormone-related genes) and 5 reference genes and quantifies the test results as a Recurrence Score (RS) to predict 10-year long-term recurrence risk and chemotherapy benefit. This test can aid in the development of breast cancer treatment plans and avoid conditions such as undertreatment or overtreatment.

Inquire Now

Features of Breast Cancer Prognosis Assessment

Genes covered by this test

Proliferation	Ki67, SKT15, Survivin, CCNB1(cyclin B1), MYBL2
HER2	GRB7, HER2
Estrogen	ER, PGR, BCL2, SCUBE2
Invasion	MMP11(stromolysin 3), CTSL2(cathepsin L2)
Reference	ACTB(β-actin), GAPDH, RPLPO, GUS, TFRC
Others	GSTM1, CD68, BAG1

Applicable Population of Breast Cancer Prognosis Assessment

Newly diagnosed breast cancer patients with stage I or II, estrogen receptor positive, lymph node metastasis negative, and to be treated with tamoxifen.
Menopausal patients with lymph node-positive, estrogen receptor-positive invasive breast cancer.

Specification of Breast Cancer Prognosis Assessment

Sample Types		Requirements
Fresh tissue	Surgical tissue	Tissue>50mg, tumor content>30%, necrotic cells<10%
Fresh tissue	Needle biopsy tissue	1-2 strips Length> 5mm, diameter 1-2mm Tumor content> 30%, necrotic cells < 10%
Paraffin specimen	Paraffin section	>10 surgical slices or >15 needle biopsy slices Area > 10mm×10mm, thickness 5-10μm Tumor content > 30%, necrotic cells < 10% Best within half a year, no more than 1 year HE stained sections or pathological results are required
Paraffin specimen	Paraffin block	Thickness of tissue-containing paraffin blocks > 100 μm Tissue surface area > 25mm² Tumor content > 30%, necrotic cells < 10% Samples kept for less than 1 year

Products

Related Solutions for Anti-cancer Therapy Documents

CCID Broad-spectrum Pathogenic Microorganism Chip Rapid Test Product Brochure

Click To View

PGS

Click To View